期刊文献+

二氯醋酸二异丙胺在肝病中的临床应用 被引量:4

下载PDF
导出
摘要 为了解二氯醋酸二异丙胺在肝病中的临床应用以指导临床用药,查阅文献,将相关二氯醋酸二异丙胺在肝病中的临床应用现状整理,发现二氯醋酸二异丙胺在非酒精性肝病和酒精性肝病治疗中有很好疗效,二氯醋酸二异丙胺与其他药物联用也有很好疗效,现介绍如下:
作者 董岚 李耀兴
出处 《中国民康医学》 2009年第8期920-921,共2页 Medical Journal of Chinese People’s Health
  • 相关文献

参考文献11

二级参考文献20

  • 1陆伦根,曾民德,茅益民,陈成伟,傅青春,王吉耀,谢渭芬,范建高,陈东风,王炳元.二氯醋酸二异丙胺治疗非酒精性脂肪性肝病的随机双盲临床研究[J].中华肝脏病杂志,2005,13(2):92-95. 被引量:37
  • 2叶维法 钟振义.当代肝脏疾病治疗学[M].成都:四川科学技术出版社,2000.558.
  • 3Angulo P, Lindor - KD. Insulin resistence and mitochondrial abnormalities in NASH:A cool look into to burning issue[J ].Gastromtreology,2001,120:1281 - 1285.
  • 4Corter - Pinto H, Camilo ME, Baptista A, et al. non - alcoholic fatty liver:another feature of the metaolic syndrome[J ]. Clin nutr, 1999,18: 353 - 358.
  • 5Song Z,Joshi-Barve S, Barve S, et al.Advances in alcoholic liver Disease. Curr Gastroenterol Rep, 2004,6 (1) : 71
  • 6江正辉.酒精与脂肪肝.见:范建高,曾民德主编.脂肪肝,第一版.上海:上海医科大学出版社,2000.127
  • 7Fox AW, Yang XQ, Murli H, et al . Absence of mutagenic effects of sodium dichloroacetate. Fundam Appl Toxicol ,1996,32:87
  • 8Arun J,Sanya L.AGA technical review on nonalcoholic fatty liver disease.Gastroenterology,2002,123:1705.
  • 9陶君 蔡卫民 张彬彬 等.安珐特与γ—干扰素抗肝纤维化的比较研究[J].中华消化病杂志,2005,9:102-105.
  • 10酒精性肝病诊断标准[J].中华肝脏病杂志,2000,8:324-329.

共引文献50

同被引文献32

  • 1朱刚剑,熊昌清,魏端,彭翔.二氯醋酸二异丙胺治疗36例酒精性脂肪肝疗效观察[J].实用肝脏病杂志,2006,9(2):93-95. 被引量:14
  • 2牛瑞云,张秀峰.老年肺结核应用抗结核药副反应的分析与护理[J].临床肺科杂志,2006,11(2):274-274. 被引量:4
  • 3崔香玉,朴红心,元艺兰.复方二氯醋酸二异丙胺治疗慢性病毒性肝炎合并酒精性肝损伤的临床疗效观察[J].临床肝胆病杂志,2007,23(4):245-246. 被引量:4
  • 4amane K, lndalao IL, Chida J, et al. Diisopropylamine dichloro- acetate, a novel pyruvate dehydrogenase kinase 4 inhibitor, as a potential therapeutic agent for metabolic disorders and multiorgan failure in severe influenza [ J ]. PLoS One, 2014,9 (5) : e98032.
  • 5Basova NE, Rozengrart EV. How the various substrates activate the process of enzymatic hydrolysis by different cholinesterases [ J ]. Zh Evol Biokhim Fiziol, 2010,46(6) :485-488.
  • 6Ng CS, Hasnat A, A1 Maruf A, et al. N-acetyltransferase 2 ( NAT2 ) genotype as a risk factor for development of drug-inducedliver injury relating to antituberculosis drug treatment in a mixed- ethnicity patient group [ J ]. Eur J Clin Pharmacol, 2014,70 (9) : 1079-1086.
  • 7Devarbhavi I-I, Andrade RJ. Drug-induced liver injury due to anti- mierobials, central nervous system agents, and nonsteroidal anti- inflammatory drugs[ J]. Semin Liver Dis, 2014,34(2) : 145-161.
  • 8Huang YS. Recent progress in genetic variation and risk of antitu- berculosis drug-induced liver injury [ J ]. J Chin Med Assoc, 2014,77(4) :169-173.
  • 9Forget E J, Menzies D. Adverse reactions to first-line antitubercu- losis drugs[J]. Expert Opin Drug Saf, 2006,5(2) :231-249.
  • 10Roy PD, Majumder M, Roy B. Pharmacogenomics of anti-TB drugs- related hepatotoxicity[J]. Pharmaeogenomies, 2008,9(3) :311-321.

引证文献4

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部